Omega-3 Fatty Acid Supplementation Has Coronary and Other Selective Health Benefits: Comprehensive Results from the VITamin D and OmegA-3 TriaL (VITAL).
Omega-3 supplements reduce heart attacks and fatal heart disease in some populations, particularly people who eat little fish, though they don't prevent cancer or all types of cardiovascular disease.
The completed VITAL RCT (n=25,871) provides the most comprehensive omega-3 FA supplementation dataset, demonstrating selective cardiac benefits (MI, fatal MI reduction) and autoimmune disease reduction without overall CVD or cancer benefit. Demographic and dietary effect modifiers suggest targeted supplementation in select populations (low fish intake, Black participants) may be warranted rather than universal recommendation.
What the study was
- Study design
- Comprehensive report of completed large randomised placebo-controlled 2×2 factorial trial (n=25,871)
- Category
- Cardiovascular-metabolic: GLP-1, SGLT2, cardiometabolic risk
- Maturity
- Potentially Practice-Changing
- Journal
- J Nutr
Why it surfaced
Comprehensive report of a landmark completed RCT providing definitive evidence on omega-3 FA supplementation across multiple endpoints; Brigham and Women's Hospital/Harvard authorship; selective benefits inform updated clinical guidance. Published as review-format summary of trial data.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.